See more : The GPT Group (GPTGF) Income Statement Analysis – Financial Results
Complete financial analysis of Hepion Pharmaceuticals, Inc. (HEPA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Hepion Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- EngageSmart, Inc. (ESMT) Income Statement Analysis – Financial Results
- Longyan Kaolin Clay Co., Ltd. (605086.SS) Income Statement Analysis – Financial Results
- Richinfo Technology Co., Ltd. (300634.SZ) Income Statement Analysis – Financial Results
- KVK Corporation (6484.T) Income Statement Analysis – Financial Results
- PT Bhakti Multi Artha Tbk (BHAT.JK) Income Statement Analysis – Financial Results
Hepion Pharmaceuticals, Inc. (HEPA)
About Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It is involved in developing Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in clinical-phase development for the treatment of non-alcoholic steatohepatitis (NASH), as well as in nonclinical studies to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH, and has demonstrated antiviral activities towards hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 67.13K | 77.46K | 86.07K | 34.52K | 26.74K | 18.79K | 21.94K | 0.00 | 21.53K | 16.36K | 0.00 | 0.00 |
| Gross Profit | -67.13K | -77.46K | -86.07K | -34.52K | -26.74K | -18.79K | -21.94K | 0.00 | -21.53K | -16.36K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 35.64M | 33.27M | 20.40M | 12.00M | 3.18M | 7.59M | 14.33M | 13.65M | 15.02M | 8.40M | 314.25K | 734.56K |
| General & Administrative | 9.62M | 10.35M | 10.01M | 8.15M | 4.59M | 7.00M | 7.28M | 7.37M | 5.79M | 5.56M | 1.36M | 106.44K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -583.71K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.62M | 10.35M | 10.01M | 8.15M | 4.59M | 7.00M | 6.69M | 7.37M | 5.79M | 5.56M | 1.36M | 106.44K |
| Other Expenses | 3.19M | 0.00 | 0.00 | 0.00 | -179.65K | -108.94K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 48.45M | 43.62M | 30.40M | 20.15M | 7.77M | 14.59M | 21.02M | 21.02M | 20.81M | 13.96M | 1.67M | 841.00K |
| Cost & Expenses | 48.45M | 43.62M | 30.40M | 20.15M | 7.77M | 14.59M | 21.04M | 21.02M | 20.81M | 13.96M | 1.67M | 841.00K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 9.47K | 10.16K | 8.86K | 31.23K | 555.00K | 339.16K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 67.13K | 77.46K | 86.07K | 34.52K | 26.74K | 18.79K | 21.94K | 27.99K | 21.53K | 16.36K | 1.32K | 841.00K |
| EBITDA | -49.26M | -43.54M | -30.32M | -20.11M | -7.74M | -14.58M | -20.62M | -21.02M | -20.81M | -13.94M | -1.67M | 0.00 |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -48.45M | -45.49M | -30.40M | -20.15M | -7.77M | -14.59M | -21.04M | -21.02M | -20.81M | -13.96M | -1.67M | -841.00K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -887.11K | 404.83K | -2.32M | -177.28K | -175.94K | 4.61M | 2.13M | 4.22M | 3.81M | -387.90K | -3.61M | -1.97K |
| Income Before Tax | -49.34M | -45.08M | -32.72M | -20.32M | -7.95M | -9.99M | -18.92M | -16.80M | -17.00M | -14.35M | -5.28M | -842.97K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 409.02K | -2.88M | 8.86K | 30.58K | -908.68K | -536.00K | -3.90M | -1.91M | -3.81M | 387.90K | 3.61M | -1.97K |
| Net Income | -48.93M | -42.20M | -32.72M | -20.35M | -7.04M | -9.45M | -15.02M | -14.89M | -17.00M | -14.35M | -5.28M | -842.97K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -12.32 | -11.07 | -9.31 | -42.06 | -68.88 | -1.03K | -2.17K | -2.86K | -7.04K | -7.39K | -4.62K | -25.55 |
| EPS Diluted | -12.32 | -11.07 | -9.31 | -42.06 | -68.88 | -1.03K | -2.17K | -2.86K | -7.04K | -7.39K | -4.62K | -25.55 |
| Weighted Avg Shares Out | 3.97M | 3.81M | 3.51M | 483.89K | 102.16K | 9.19K | 6.91K | 5.20K | 2.42K | 1.94K | 1.14K | 33.00K |
| Weighted Avg Shares Out (Dil) | 3.97M | 3.81M | 3.51M | 483.89K | 102.16K | 9.19K | 6.91K | 5.21K | 2.42K | 1.94K | 1.14K | 33.00K |
ENDRA Life Sciences and Hepion Pharmaceuticals Partner to Drive Efficiencies in NASH Clinical Trials
Hepion to include ENDRA's TAEUS Ⓡ technology in Phase 2b trial of CRV431 ANN ARBOR, MI and EDISON, NJ / ACCESSWIRE / March 18, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), and...
Why Hepion Pharma, Sesen Bio And More Are Moving Today
Hepion Pharmaceuticals (NASDAQ: HEPA) shares are trading lower Tuesday after the company priced its 44.2 million share common stock offering at $2 per share. Hepion Pharmaceuticals Inc is engaged in the development of targeted pharmaceutical therapies for liver disease.
Hepion Pharmaceuticals Announces Pricing of Public Offering
EDISON, N.J., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis ("NASH"), today announced the pricing of...
Attractive Risk-Reward Profile For Hepion Pharmaceuticals
Hepion's leading candidate CRV431 may have the best anti-fibrotic effect among the numerous NASH candidates. CRV431's analogs have been widely studied in various clinical trials, and were proven to be well-tolerated.
Hepion Pharmaceuticals to Participate in Upcoming January Virtual Investor Conferences
EDISON, NJ / ACCESSWIRE / January 5, 2021 / Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA)("Hepion"), a clinical stage biopharmaceutical company focused on Artificial Intelligence ("AI")-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis ("NASH") and liver disease, announced today that management...
Hepion Pharmaceuticals Announces Positive Top Line Data for Low Dose CRV431 in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
CRV431 Demonstrated to be Generally Safe and Well Tolerated Clinically Significant Reductions in Important Biomarkers, ALT and AST, Observed in 28 Days Study Continuing with Higher Dose EDISON, NJ / ACCESSWIRE / December 29 , 2020 / Hepion Pharmaceuticals, Inc....
Hepion Pharmaceuticals Data Safety Monitoring Board Recommends Continuation with Final Dose Cohort in Phase 2a 'AMBITION' Clinical Trial for Treatment of Advanced NASH
- DSMB Review After Completion of the First Dose Cohort Affirmed No Safety or Tolerability Concerns with CRV431 in NASH Patients - - DSMB Recommended the AMBITION Study Continue with Final Dosing Cohort - - Final Cohort Expected to be...
Hepion Pharmaceuticals Announces FDA Clearance of IND Application for CRV431 for COVID-19
- IND Expands Potential Indications for CRV431 Beyond NASH to Include COVID-19 - - CRV431 Poised to Move Directly into Phase 2 Clinical Study for COVID-19 - - Company May Seek Partnership(s) for COVID-19 Drug Development - EDISON, NJ /...
Terns Pharmaceuticals to Present Clinical Data on Improved TERN-101 Tablet Formulation at the Paris NASH Digital Experience
Terns Pharmaceuticals to Present Clinical Data on Improved TERN-101 Tablet Formulation at the Paris NASH Digital Experience
Poxel dresse un bilan de ses activités et publie sa position de trésorerie et son chiffre d’affaires du troisième trimestre et des neuf premiers mois de 2020
Regulatory News: POXEL (Euronext – POXEL - FR0012432516, éligible PEA-PME), société biopharmaceutique spécialisée dans le développement de traitements
Source: https://incomestatements.info
Category: Stock Reports